Summary
Introduction
The renin-angiotensin system is one of the important systems in the control of aldosterone secretion and of the arterial blood pressure. Angiotensin I1 and the heptapeptide Desl-angiotensin I1 are its biologically active compounds. The relative importance of each of the two substances is still not clear since it is extremely difficult to measure them both simultaneously and separately in plasma. Studies in vivo and experiments in vitro, however, have shown that the vasopressor activity of the heptapeptide is smaller than of the octapeptide angiotensin I1 whereas the aldosterone-stimulating potencies of both substances seem to be almost identical (Bumpus, Khairallah, Arakawa, Page & Smeby, 1961 ; Blair-West, CoghIan, Denton, Funder, Scoggins & Wright, 1971) . Recently, it has been proposed that Desl-angiotensin 11, called sometimes also angiotensin 111, is more important than angiotensin I1 in the control of aldosterone secretion (Peach & Chiu, 1974; Campbell, Brooks & Pettinger, 1974;  Goodfriend & Peach, 1975; Bravo, Khoshla & Bumpus, 1975) . We have performed experiments which may help to elucidate further the role of angiotensin I1 and of its heptapeptide metabolite in the control of the blood pressure and of aldosterone secretion.
Methods
Mongrel dogs, fed with a standard laboratory diet, were used for this study. They were anaesthetized with thiopental and given 2 mg of dexamethasone intramuscularly 14 h and 1 h before the start of an experiment. Infusions were performed through a catheter placed in a femoral vein. Blood was drawn through the opposite femoral vein. A catheter was placed via the right femoral artery into the abdominal aorta for the continuous measurement of the arterial blood pressure.
Substances for infusions were dissolved in 154 mmol/l sodium chloride (9 g/l ; physiological saline) and infused in volumes approximately equal to the blood loss. A 6 ml blood sample was necessary for the measurement of plasma aldosterone and plasma renin activity.
Experiment 1
After control measurements of arterial blood pressure and collection of control blood samples either angiotensin I1 (Asp'-Ile5-angiotensin 11, Schwarz-Mann) or Des-AspL-lle5-angiotensin I1 (heptapeptide, Schwarz-Mann) were infused in three different concentrations (5, 50 and 200 pmol min-l kg-I). Each infusion lasted 45 min. Blood was drawn at the end of each infusion and 20, 40, 60 and 90 min after the end of the last infusion, when only saline was administered.
Experiment 2
Two groups of dogs were infused either with angiotensin I1 or with Desl-angiotensin I1 (20 pmol min-kg-I ) . The angiotensin antagonist Sarl-Alaaangiotensin I1 (saralasin acetate, Norwich Pharmacal) was added after 60 min ( kg-') for 60 min. Blood was drawn at regular intervals during the experiment, Plasma aldosterone was measured by radioimrnunoassay (Vetter, Vetter & Siegenthaler, 1973) and plasma renin activity was measured by radioimmunoassay of angiotensin I (Beckerhoff, Nussberger, Vetter & Siegenthaler, 1975a) .
Results

Experiment 1
Both peptides induced an increase in plasma aldosterone without a significant difference between angiotensin I1 and Desl-angiotensin I1 (Fig. 1 ) . Plasma aldosterone decreased, however, significantly faster after the end of the last infusion in the heptapeptide group (P < 0.005). Aldosterone concentrations were almost identical in both groups at the end of the experiment. Plasma renin activity was significantly suppressed from 3.0f0.54 ng 3 h-l m1-I ( m e a n f~~~) to 054f0.15 ng 3 h-I ml-I by angiotensin I1 infusions and from 2.54k0.62 ng 3 h-I m1-I to 0.15 f O . 0 ng 3 h-' ml-' by heptapeptide infusions (P<O.O5).
Although the values were lower during heptapeptide infusions the differences were not significant. The differences between the two groups were insignificant also after the infusions. The arterial blood pressure rose when the peptides were administered and decreased again after the end of the last infusion. The increase induced by the heptapeptide was, however, only 4342% of the increase induced by equimolar doses of angiotensin 11.
Experiment 2
Plasma aldosterone increased in all dogs during the infusions of angiotensin I1 or of Desl-angiotensin I1 (20 pmol min-l kg-'). When Sar1-Ala8-angiotensin I1 was added (200 pmol mind' kg-l) aldosterone increased further slightly in the angiotensin I1 group whereas it remained almost unchanged in heptapeptide-treated animals. Aldosterone decreased and reached or fell below the control values in all dogs infused with the heptapeptide when Sar1-Ala8-angiotensin I1 was increased to 400 pmol min-kg-I .
Plasma aldosterone decreased also in animals infused with angiotensin 11. However, the plasma concentration remained significantly higher (P < 0.05) and was more than twice as high as the control values before the start of the experiment. Plasma aldosterone increased markedly in all dogs when after termination of saralasin the angiotensin I1 or Desl-angiotensin I1 infusions were continued. The increase was lower in dogs receiving the heptapeptide. The difference between the two groups was significant at 20, 40 and 60 min after the end of saralasin (P~0.02 or less). Plasma renin activity decreased when angiotensin I1 or heptapeptide was infused (from 2.31 k0.46 to 0.31 k0.08 ng 3 h-' ml-in angiotensin 11-treated dogs and from 1.23 k 0.31 to 0.77 f0.46 ng 3 h-' ml-' in heptapeptidetreated animals). With the addition of the antagonist, plasma renin activity increased to 2.78 k 1.16 ng 3 h-' m1-I and to 0.93 f0.39 ng 3 h-l ml-I respectively. Renin activity fell again after termination of theantagonist infusions to 0.77 f0.31 ng 3 h-I m1-I and 0.54k0.23 ng 3 h-I m1-I respectively. At no point of the experiment was there a significant difference between the two groups of dogs.
Discussion
Our experiments confirm previous observations that angiotensin I1 and Desl-angiotensin I1 possess an almost equal aldosteronestimulating potency (BlairWest et af., 1971; Spielman, Davis, Freeman & Johnson, 1974) . Both peptides also suppress plasma renin activity significantly and to essentially the same degree (Lohmeier, Davis & Freeman, 1975) , whereas the rise in arterial pressure induced by the heptapeptide is significantly lower than that produced by angiotensin I1 (Bumpus et af., 1961) . In addition our experiments revealed the following further differences between angiotensin I1 and Desl-angiotensin 11. (1) Plasma aldosterone decreased significantly faster after the end of heptapeptide than of angiotensin I1 infusions (experiment 1 ) . The faster decline may be explained by a longer action of angiotensin I1 at the adrenal cortex although its half-life after intravenous injection is only a few minutes. (2) Sar*-Ala8-angiotensin I1 (400 pmol min-I kg-I) blocked completely the aldosterone response to the heptapeptide (20 pmol min-kg-I ) and plasma aldosterone was only partly suppressed in dogs infused with equimolar doses of angiotensin I1 (experiment 2). This observation is in contrast to findings of Campbell et af. (1974) in the rat and of Bravo et af. (1975) in dogs. The latter investigators, however, used Sar1-Ile8-angiotensin I1 as inhibitor, which might cause confusion since it possesses a potent intrinsic steroidogenic potency (Beckerhoff, Uhlschmid, Furrer, Nussberger, Schmied, Vetter & Siegenthaler, 1975b) . The data presented here seem to indicate that Sar'-Ala8-angiotensin I1 displaces Desl-angiotensin I1 more easily from its adrenal cortical receptor than angiotensin 11. (3) The high increase of plasma aldosterone after the end of Sar1-Ala8-angiotensin I1 infusion in both groups of dogs was surprising. One possible explanation for this observation may be that pretreatment with the antagonist rendered the adrenal gland more sensitive to angiotensin I1 and to Deslangiotensin 11, which at the start of the experiment had in the same concentrations induced only a moderate increase in plasma aldosterone. Although plasma aldosterone increased in both groups after the end of the antagonist infusions the increase was significantly higher in angiotensin 11-treated dogs. Since there were no significant differences in plasma renin activity, which was relatively low in all animals, endogenous angiotensin I1 cannot explain the observed changes of plasma aldosterone. The higher increase in angiotensin 11-infused dogs may also be explained by a stronger affinity of this peptide to its adrenal receptors. Obviously, not only are higher doses of saralasin necessary to block the steroidogenic activity of angiotensin 11; Sar1-Ala8-angiotensin I1 is also more easily displaced from the receptor by angiotensin I1 than by Des'-angiotensin 11.
The results of the experiments in vivo presented here do not support the hypothesis that Desl-angiotensin I1 is the main agonist at the adrenal cortex. They rather suggest that the affinity of angiotensin 11 to the adrenal cortex is higher than that of the heptapeptide, favouring an important role of the octapeptide angiotensin I1 in the control of aldosterone secretion.
